← FDA DRUG APPROVALS

FDA ANDA · ANDA065431

AMOXICILLIN AND CLAVULANATE POTASSIUM

Sponsor: CIPLA

APPLICATION
ANDA065431
TYPE
ANDA
ORIGINAL APPROVAL
2008-11-25
LATEST ACTION
2016-05-12
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

AMOXICILLIN AND CLAVULANATE POTASSIUMPrescription
AMOXICILLIN 250MG/5ML, CLAVULANATE POTASSIUM EQ 62.5MG BASE/5ML · FOR SUSPENSION · ORAL

Approval history

2016-05-12Labeling · Supplement 7 · standardAP
2008-11-25OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →